{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:54:48Z","timestamp":1791266088100,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"DOI":"10.1007\/s10787-026-02409-w","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:23:18Z","timestamp":1791264198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bone and growth safety profiles of biologic and conventional DMARDs in juvenile idiopathic arthritis: a 21-year FAERS disproportionality analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9228-2866","authenticated-orcid":false,"given":"Fatih","family":"Erdem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nida","family":"G\u00fcrb\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"2409_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/pds.5547","volume":"32","author":"EK Acton","year":"2023","unstructured":"Acton EK, Willis AW, Hennessy S (2023) Core concepts in pharmacoepidemiology: key biases arising in pharmacoepidemiologic studies. Pharmacoepidemiol Drug Saf 32:9\u201318. https:\/\/doi.org\/10.1002\/pds.5547","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2409_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A et al (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54:315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"key":"2409_CR3","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1136\/ard.2005.048835","volume":"65","author":"JM Burnham","year":"2006","unstructured":"Burnham JM, Shults J, Weinstein R, Lewis JD, Leonard MB (2006) Childhood onset arthritis is associated with an increased risk of fracture: a population based study using the General Practice Research Database. Ann Rheum Dis 65:1074\u20131079. https:\/\/doi.org\/10.1136\/ard.2005.048835","journal-title":"Ann Rheum Dis"},{"key":"2409_CR4","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1002\/art.23683","volume":"58","author":"JM Burnham","year":"2008","unstructured":"Burnham JM, Shults J, Dubner SE, Sembhi H, Zemel BS, Leonard MB (2008) Bone density, structure, and strength in juvenile idiopathic arthritis: importance of disease severity and muscle deficits. Arthritis Rheum 58:2518\u20132527. https:\/\/doi.org\/10.1002\/art.23683","journal-title":"Arthritis Rheum"},{"key":"2409_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1172\/JCI119207","volume":"99","author":"F De Benedetti","year":"1997","unstructured":"De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V et al (1997) Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I: a model for stunted growth in children with chronic inflammation. J Clin Invest 99:643\u2013650. https:\/\/doi.org\/10.1172\/JCI119207","journal-title":"J Clin Invest"},{"key":"2409_CR6","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I et al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367:2385\u20132395. https:\/\/doi.org\/10.1056\/NEJMoa1112802","journal-title":"N Engl J Med"},{"key":"2409_CR7","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/art.38984","volume":"67","author":"F De Benedetti","year":"2015","unstructured":"De Benedetti F, Brunner H, Ruperto N, Schneider R, Xavier R, Allen R et al (2015) Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol 67:840\u2013848. https:\/\/doi.org\/10.1002\/art.38984","journal-title":"Arthritis Rheumatol"},{"key":"2409_CR8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/pds.3622","volume":"23","author":"P de Boissieu","year":"2014","unstructured":"de Boissieu P, Kanagaratnam L, Abou Taam M, Roux MP, Drame M, Trenque T (2014) Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database. Pharmacoepidemiol Drug Saf 23:989\u2013992. https:\/\/doi.org\/10.1002\/pds.3622","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2409_CR9","first-page":"1305","volume":"31","author":"O di Munno","year":"2004","unstructured":"di Munno O, Mazzantini M, Sinigaglia L, Bianchi G, Minisola G, Muratore M et al (2004) Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol 31:1305\u20131309","journal-title":"J Rheumatol"},{"key":"2409_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel W (1999) Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 53:177\u2013190. https:\/\/doi.org\/10.1080\/00031305.1999.10474456","journal-title":"Am Stat"},{"key":"2409_CR11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V et al (2024a) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement. Drug Saf 47:575\u2013584. https:\/\/doi.org\/10.1007\/s40264-024-01421-9","journal-title":"Drug Saf"},{"key":"2409_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V et al (2024b) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration. Drug Saf 47:585\u2013599. https:\/\/doi.org\/10.1007\/s40264-024-01423-7","journal-title":"Drug Saf"},{"key":"2409_CR13","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2016.16435","volume":"316","author":"DN Kyriacou","year":"2016","unstructured":"Kyriacou DN, Lewis RJ (2016) Confounding by indication in clinical research. JAMA 316:1818\u20131819. https:\/\/doi.org\/10.1001\/jama.2016.16435","journal-title":"JAMA"},{"key":"2409_CR14","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/jbmr.2511","volume":"30","author":"CMA LeBlanc","year":"2015","unstructured":"LeBlanc CMA, Ma J, Taljaard M, Roth J, Scuccimarri R, Miettunen P et al (2015) Incident vertebral fractures and risk factors in the first three years following glucocorticoid initiation among pediatric patients with rheumatic disorders. J Bone Min Res 30:1667\u20131675. https:\/\/doi.org\/10.1002\/jbmr.2511","journal-title":"J Bone Min Res"},{"issue":"Suppl 3","key":"2409_CR15","doi-asserted-by":"publisher","first-page":"iii3","DOI":"10.1093\/rheumatology\/keg492","volume":"42","author":"TM MacDonald","year":"2003","unstructured":"MacDonald TM, Pettitt D, Lee FH, Schwartz JS (2003) Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes. Rheumatology (Oxford) 42(Suppl 3):iii3\u2013iii10. https:\/\/doi.org\/10.1093\/rheumatology\/keg492","journal-title":"Rheumatology (Oxford)"},{"key":"2409_CR16","first-page":"1520","volume":"29","author":"PJ Manners","year":"2002","unstructured":"Manners PJ, Bower C (2002) Worldwide prevalence of juvenile arthritis: Why does it vary so much? J Rheumatol 29:1520\u20131530","journal-title":"J Rheumatol"},{"key":"2409_CR17","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1002\/sim.2473","volume":"25","author":"GN Nor\u00e9n","year":"2006","unstructured":"Nor\u00e9n GN, Bate A, Orre R, Edwards IR (2006) Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med 25:3740\u20133757. https:\/\/doi.org\/10.1002\/sim.2473","journal-title":"Stat Med"},{"key":"2409_CR18","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/acr.24853","volume":"74","author":"KB Onel","year":"2022","unstructured":"Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST et al (2022a) 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 74:521\u2013537. https:\/\/doi.org\/10.1002\/acr.24853","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2409_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/acr.24839","volume":"74","author":"KB Onel","year":"2022","unstructured":"Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST et al (2022b) 2021 American college of rheumatology guideline for the treatment of juvenile idiopathic arthritis: recommendations for nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Arthritis Care Res (Hoboken) 74:505\u2013520. https:\/\/doi.org\/10.1002\/acr.24839","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2409_CR20","first-page":"2445","volume":"25","author":"S Ozen","year":"1998","unstructured":"Ozen S, Karaaslan Y, Ozdemir O, Saatci U, Bakkaloglu A, Koroglu E et al (1998) Prevalence of juvenile chronic arthritis and familial Mediterranean fever in Turkey: a field study. J Rheumatol 25:2445\u20132449","journal-title":"J Rheumatol"},{"key":"2409_CR21","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N (2007) Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 30:891\u2013898. https:\/\/doi.org\/10.2165\/00002018-200730100-00007","journal-title":"Drug Saf"},{"key":"2409_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/sim.4780100409","volume":"10","author":"H Petri","year":"1991","unstructured":"Petri H, Urquhart J (1991) Channeling bias in the interpretation of drug effects. Stat Med 10:577\u2013581. https:\/\/doi.org\/10.1002\/sim.4780100409","journal-title":"Stat Med"},{"key":"2409_CR23","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al (2004) International League of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390\u2013392","journal-title":"J Rheumatol"},{"key":"2409_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00198-020-05664-x","volume":"32","author":"F Robin","year":"2021","unstructured":"Robin F, Cadiou S, Albert JD, Bart G, Coiffier G, Guggenbuhl P (2021) Methotrexate osteopathy: five cases and systematic literature review. Osteoporos Int 32:225\u2013232. https:\/\/doi.org\/10.1007\/s00198-020-05664-x","journal-title":"Osteoporos Int"},{"key":"2409_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/acr.20589","volume":"64","author":"C Rodd","year":"2012","unstructured":"Rodd C, Lang B, Ramsay T, Alos N, Huber AM, Cabral DA et al (2012) Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study. Arthritis Care Res (Hoboken) 64:122\u2013131. https:\/\/doi.org\/10.1002\/acr.20589","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2409_CR26","doi-asserted-by":"publisher","first-page":"151952","DOI":"10.1016\/j.semarthrit.2022.151952","volume":"52","author":"N Ruffer","year":"2022","unstructured":"Ruffer N, Krusche M, Beil FT, Amling M, K\u00f6tter I, Rolvien T (2022) Clinical features of methotrexate osteopathy in rheumatic musculoskeletal disease: a systematic review. Semin Arthritis Rheum 52:151952. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151952","journal-title":"Semin Arthritis Rheum"},{"key":"2409_CR27","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/art.23087","volume":"57","author":"JJ Sacks","year":"2007","unstructured":"Sacks JJ, Helmick CG, Luo YH, Ilowite NT, Bowyer S (2007) Prevalence of and annual ambulatory health care visits for pediatric arthritis and other rheumatologic conditions in the United States in 2001\u20132004. Arthritis Rheum 57:1439\u20131445. https:\/\/doi.org\/10.1002\/art.23087","journal-title":"Arthritis Rheum"},{"key":"2409_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12969-021-00613-2","volume":"19","author":"S Sahin","year":"2021","unstructured":"Sahin S, Acari C, Sonmez HE, Kilic FZ, Sag E, Dundar HA et al (2021) Frequency of juvenile idiopathic arthritis and associated uveitis in pediatric rheumatology clinics in Turkey: a retrospective study, JUPITER. Pediatr Rheumatol Online J 19:134. https:\/\/doi.org\/10.1186\/s12969-021-00613-2","journal-title":"Pediatr Rheumatol Online J"},{"key":"2409_CR29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 10:796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"key":"2409_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry S, Fautrel B, Lemelle I, Guillemin F (2014) Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine 81:112\u2013117. https:\/\/doi.org\/10.1016\/j.jbspin.2013.09.003","journal-title":"Joint Bone Spine"},{"key":"2409_CR31","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1136\/adc.2006.093997","volume":"91","author":"J Thornton","year":"2006","unstructured":"Thornton J, Ashcroft DM, Mughal MZ, Elliott RA, O\u2019Neill TW, Symmons D (2006) Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis. Arch Dis Child 91:753\u2013761. https:\/\/doi.org\/10.1136\/adc.2006.093997","journal-title":"Arch Dis Child"},{"key":"2409_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11:3\u201310. https:\/\/doi.org\/10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2409_CR33","doi-asserted-by":"publisher","first-page":"e5195","DOI":"10.1210\/clinem\/dgab494","volume":"106","author":"LM Ward","year":"2021","unstructured":"Ward LM, Ma J, Robinson ME, Scharke M, Ho J, Houghton K et al (2021) Osteoporotic fractures and vertebral body reshaping in children with glucocorticoid-treated rheumatic disorders. J Clin Endocrinol Metab 106:e5195\u2013e5207. https:\/\/doi.org\/10.1210\/clinem\/dgab494","journal-title":"J Clin Endocrinol Metab"},{"key":"2409_CR34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jocd.2019.07.002","volume":"22","author":"DR Weber","year":"2019","unstructured":"Weber DR, Boyce A, Gordon C, H\u00f6gler W, Kecskemethy HH, Misra M et al (2019) The utility of DXA assessment at the forearm, proximal femur, and lateral distal femur, and vertebral fracture assessment in the pediatric population: 2019 ISCD official position. J Clin Densitom 22:567\u2013589. https:\/\/doi.org\/10.1016\/j.jocd.2019.07.002","journal-title":"J Clin Densitom"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02409-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02409-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02409-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:23:19Z","timestamp":1791264199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-026-02409-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":34,"alternative-id":["2409"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02409-w","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The FAERS database is fully de-identified and publicly released by the U.S. FDA for research purposes. Secondary analysis of de-identified, publicly available pharmacovigilance data does not constitute human subjects research and did not require ethics committee approval or informed consent.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used only de-identified, publicly available aggregate spontaneous-report data; no individual participants were involved.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}